Skip to main content
. 2021 Apr 12;118(16):e2000017118. doi: 10.1073/pnas.2000017118

Fig. 4.

Fig. 4.

BMS-986122 (BMS) produces antinociception against inflammatory pain in 129S1/Svlmj mice. Paw withdrawal thresholds were assessed in the right hindpaw 30 min after BMS (10 mg/kg, i.p.). Mice received either bilateral (A) or unilateral (B) intraplantar injections of carrageenan, and mechanical allodynia was assessed in the right hindpaw by sensitivity to von Frey filaments. Carrageenan produced robust mechanical allodynia in the right hindpaw 24 h after injection, compared with preinjury baseline (BL), after both unilateral [main effect of treatment: F(3,50) = 22.07, P < 0.0001, n = 6 ****P < 0.0001] and bilateral injections [main effect of treatment: F(3,46) = 19.05, P < 0.0001, n =6, ****P < 0.0001]. A single systemic injection of BMS reversed allodynia in mice with bilateral inflammation (*P < 0.05, n = 6) in a naloxone (NLX) reversible manner (#P < 0.05). (C) Sustained antiallodynic effects of BMS against CFA-induced unilateral inflammation after twice daily injections for 3 d. Main effect of treatment: F(1,10) = 69.51, P < 0.0001; n = 6. **P < 0.01, ***P < 0.001. (D) Reversal of pain-depressed nesting behavior following i.p. injections of BMS. i.p. injection of dilute acetic acid depressed nesting, which was restored by BMS. Main effect of treatment: F(2,16) = 24.58, P < 0.0001, n = 6. ****P < 0.0001 versus vehicle or morphine.